Summary of Published Drug and Supplement NHLBI Trials, 1970–2012.

a. The CDP trial did not show mortality benefits with the original follow-up period. If we had analyzed the subsequent follow-up trial that was not apriori, treatment with niacin would have shown a significant benefit to total mortality.
b. The PREVENT study was stopped early for effectiveness seen in the primary outcome. The number of deaths reported shows a null effect on total mortality; but this study might have shown a benefit for total mortality had the full follow-up been completed. We report it here as significant but it will show as null in the meta-analyses.
c. The SANDS study did not show any differences on total mortality or reduction of cardiovascular disease events. However, the treatment arm experienced significantly more adverse events. SANDS study authors concluded that there may not be favorable long-term outcomes for participants randomized to treatment.
d. Chi-square test uses the Yates correction for continuity.
Summary of Published Drug and Supplement NHLBI Trials, 1970–2012.